Research programme: TAM inhibitors - Halia Therapeutics
Latest Information Update: 12 Jul 2022
At a glance
- Originator Halia Therapeutics
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Axl receptor tyrosine kinase inhibitors; Proto-oncogene protein c-mer inhibitors; TYRO3 receptor protein tyrosine kinase antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Inflammation; Neurodegenerative disorders
Most Recent Events
- 21 Jun 2022 Early research in Inflammation in USA (unspecified route) before June 2022 (Halia Therapeutics pipeline, June 2022)
- 21 Jun 2022 Early research in Neurodegenerative disorders in USA (unspecified route) before June 2022 (Halia Therapeutics pipeline, June 2022)